{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T18:50:40Z","timestamp":1781117440096,"version":"3.54.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T00:00:00Z","timestamp":1618617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T00:00:00Z","timestamp":1618617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s40123-021-00345-2","type":"journal-article","created":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T07:02:55Z","timestamp":1618642975000},"page":"337-348","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Real-World Safety Outcomes of Intravitreal Ranibizumab Biosimilar (Razumab) Therapy for Chorioretinal Diseases"],"prefix":"10.1007","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9693-7882","authenticated-orcid":false,"given":"Debdulal","family":"Chakraborty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay U.","family":"Sheth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tushar K.","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhendu","family":"Boral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnab","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumen","family":"Mondal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angshuman","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,17]]},"reference":[{"key":"345_CR1","doi-asserted-by":"crossref","first-page":"556","DOI":"10.2337\/dc11-1909","volume":"35","author":"JW Au","year":"2012","unstructured":"Au JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35:556\u201364.","journal-title":"Diabetes Care"},{"issue":"4","key":"345_CR2","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1159\/000329603","volume":"47","author":"E Prokofyeva","year":"2012","unstructured":"Prokofyeva E, Zrenner E. Epidemiology of major eye diseases leading to blindness in Europe: a literature review. Ophthalmic Res. 2012;47(4):171\u201388.","journal-title":"Ophthalmic Res"},{"issue":"2","key":"345_CR3","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","volume":"2","author":"WL Wong","year":"2014","unstructured":"Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106\u201316.","journal-title":"Lancet Glob Health"},{"key":"345_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vhri.2018.11.002","volume":"19","author":"P Jaki Mekjavi\u0107","year":"2019","unstructured":"Jaki Mekjavi\u0107 P, J\u016brat\u0117 Bal\u010di\u016bnien\u0117 V, \u0106ekli\u0107 L, et al. The burden of macular diseases in central and eastern Europe\u2014implications for healthcare systems. Value Health Reg Issues. 2019;19:1\u20136.","journal-title":"Value Health Reg Issues"},{"issue":"4","key":"345_CR5","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1001\/archopht.116.4.514","volume":"116","author":"RA Williams","year":"1998","unstructured":"Williams RA, Brody BL, Thomas RG, Kaplan RM, Brown SI. The psychosocial impact of macular degeneration. Arch Ophthalmol. 1998;116(4):514\u201320.","journal-title":"Arch Ophthalmol"},{"issue":"14","key":"345_CR6","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/1471-2415-14-78","volume":"12","author":"SR Dawson","year":"2014","unstructured":"Dawson SR, Mallen CD, Gouldstone MB, Yarham R, Mansell G. The prevalence of anxiety and depression in people with age-related macular degeneration: a systematic review of observational study data. BMC Ophthalmol. 2014;12(14):78.","journal-title":"BMC Ophthalmol"},{"issue":"2","key":"345_CR7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40662-015-0026-2","volume":"30","author":"R Lee","year":"2015","unstructured":"Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis (Lond). 2015;30(2):17.","journal-title":"Eye Vis (Lond)"},{"issue":"87","key":"345_CR8","first-page":"44","volume":"27","author":"D Yorston","year":"2014","unstructured":"Yorston D. Anti-VEGF drugs in the prevention of blindness. Community Eye Health. 2014;27(87):44\u20136.","journal-title":"Community Eye Health"},{"issue":"5","key":"345_CR9","doi-asserted-by":"publisher","first-page":"CD012208","DOI":"10.1002\/14651858.CD012208.pub2","volume":"5","author":"E Li","year":"2020","unstructured":"Li E, Donati S, Lindsley KB, Krzystolik MG, Virgili G. Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2020;5(5):CD012208. https:\/\/doi.org\/10.1002\/14651858.CD012208.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"345_CR10","doi-asserted-by":"crossref","first-page":"328","DOI":"10.2174\/1573399811666150615151324","volume":"17","author":"C Campa","year":"2016","unstructured":"Campa C, Alivernini G, Bolletta E, Parodi MB, Perri P. Anti-VEGF therapy for retinal vein occlusions. Curr Drug Targets. 2016;17(3):328\u201336.","journal-title":"Curr Drug Targets"},{"key":"345_CR11","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2147\/OPTH.S236637","volume":"14","author":"SE Mansour","year":"2020","unstructured":"Mansour SE, Browning DJ, Wong K, Flynn HW Jr, Bhavsar AR. The evolving treatment of diabetic retinopathy. Clin Ophthalmol. 2020;14:653\u201378.","journal-title":"Clin Ophthalmol"},{"issue":"7","key":"345_CR12","doi-asserted-by":"crossref","first-page":"596","DOI":"10.4103\/ijo.IJO_992_16","volume":"65","author":"P Jain","year":"2017","unstructured":"Jain P, Sheth J, Anantharaman G, Gopalakrishnan M. Real-world evidence of safety profile of intravitreal bevacizumab (Avastin) in an Indian scenario. Indian J Ophthalmol. 2017;65(7):596\u2013602.","journal-title":"Indian J Ophthalmol"},{"key":"345_CR13","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.2147\/OPTH.S180393","volume":"12","author":"A Sharma","year":"2018","unstructured":"Sharma A, Reddy P, Kuppermann BD, Bandello F, Lowenstein A. Biosimilars in ophthalmology: \u201cis there a big change on the horizon?\u201d Clin Ophthalmol. 2018;12:2137\u201343.","journal-title":"Clin Ophthalmol"},{"issue":"2","key":"345_CR14","first-page":"368","volume":"6","author":"S Sharma","year":"2018","unstructured":"Sharma S, Khan MA, Chaturvedi A, RE-ENACT Study Investigators Group. Real life clinical effectiveness of Razumab\u00ae (World\u2019s First Biosimilar Ranibizumab) in wet age-related macular degeneration: a subgroup analysis of pooled retrospective RE-ENACT study. Int J Ophthalmol Eye. 2018;6(2):368\u201373.","journal-title":"Int J Ophthalmol Eye"},{"issue":"1","key":"345_CR15","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000488602","volume":"241","author":"S Sharma","year":"2019","unstructured":"Sharma S, Khan MA, Chaturvedi A, RE-ENACT Study Investigators Group. Real-life clinical effectiveness of Razumab\u00ae (the World\u2019s First Biosimilar of Ranibizumab) in retinal vein occlusion: a subgroup analysis of the pooled retrospective RE-ENACT study. Ophthalmologica. 2019;241(1):24\u201331.","journal-title":"Ophthalmologica"},{"issue":"2","key":"345_CR16","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.survophthal.2010.08.006","volume":"56","author":"M Tolentino","year":"2011","unstructured":"Tolentino M. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol. 2011;56(2):95\u2013113.","journal-title":"Surv Ophthalmol"},{"issue":"7","key":"345_CR17","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/eye.2013.107","volume":"27","author":"KG Falavarjani","year":"2013","unstructured":"Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond). 2013;27(7):787\u201394.","journal-title":"Eye (Lond)"},{"key":"345_CR18","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.4103\/ijo.IJO_430_19","volume":"67","author":"A Sharma","year":"2019","unstructured":"Sharma A, Kumar N, Kuppermann B, Francesco B, Lowenstein A. Ophthalmic biosimilars: lessons from India. Indian J Ophthalmol. 2019;67:1384.","journal-title":"Indian J Ophthalmol"},{"key":"345_CR19","unstructured":"https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use_en-15.pdf. Accessed 27 Feb 2021."},{"issue":"4","key":"345_CR20","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.ajo.2007.06.039","volume":"144","author":"DM Brown","year":"2007","unstructured":"Brown DM, Regillo CD. Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. Am J Ophthalmol. 2007;144(4):627\u201337.","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"345_CR21","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ophtha.2018.07.028","volume":"126","author":"SJ Bakri","year":"2019","unstructured":"Bakri SJ, Thorne JE, Ho AC, et al. Safety and efficacy of anti-vascular endothelial growth factor therapies for neovascular age-related macular degeneration: a report by the American Academy of Ophthalmology [published correction appears in Ophthalmology. 2019 Jun;126(6):915]. Ophthalmology. 2019;126(1):55\u201363.","journal-title":"Ophthalmology"},{"issue":"6","key":"345_CR22","first-page":"CD007419","volume":"6","author":"G Virgili","year":"2017","unstructured":"Virgili G, Parravano M, Evans JR, Gordon I, Lucenteforte E. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. Cochrane Database Syst Rev. 2017;6(6):CD007419.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"345_CR23","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1159\/000497492","volume":"242","author":"K Spooner","year":"2019","unstructured":"Spooner K, Hong T, Fraser-Bell S, Chang AA. Current outcomes of anti-VEGF therapy in the treatment of macular oedema secondary to branch retinal vein occlusions: a meta-analysis. Ophthalmologica. 2019;242(3):163\u201377.","journal-title":"Ophthalmologica"},{"issue":"5","key":"345_CR24","doi-asserted-by":"crossref","first-page":"e022031","DOI":"10.1136\/bmjopen-2018-022031","volume":"9","author":"B Pham","year":"2019","unstructured":"Pham B, Thomas SM, Lillie E, et al. Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis. BMJ Open. 2019;9(5):e022031.","journal-title":"BMJ Open"},{"key":"345_CR25","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s40123-019-00228-7","volume":"9","author":"S Sharma","year":"2020","unstructured":"Sharma S, Khan M, Chaturvedi A, RE-ENACT 2 Study Investigators Group. A multicenter, retrospective study (RE-ENACT 2) on the use of Razumab\u2122 (World\u2019s First Biosimilar Ranibizumab) in wet age-related macular degeneration. Ophthalmol Ther. 2020;9:103\u201314.","journal-title":"Ophthalmol Ther"},{"key":"345_CR26","doi-asserted-by":"crossref","unstructured":"Sharma S, RE-ENACT 2 Study Investigators Group, Khan M, Chaturvedi A. A multicenter, retrospective study (RE-ENACT 2) on Razumab\u2122 (World\u2019s First Biosimilar Ranibizumab) in retinal vein occlusion. Ophthalmol Ther. 2020;9:625\u201339.","DOI":"10.1007\/s40123-020-00277-3"},{"issue":"1","key":"345_CR27","doi-asserted-by":"crossref","first-page":"13248","DOI":"10.1038\/s41598-020-70269-7","volume":"10","author":"VA De Vries","year":"2020","unstructured":"De Vries VA, Bassil FL, Ramdas WD. The effects of intravitreal injections on intraocular pressure and retinal nerve fiber layer: a systematic review and meta-analysis. Sci Rep. 2020;10(1):13248.","journal-title":"Sci Rep"},{"issue":"4","key":"345_CR28","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ophtha.2018.11.019","volume":"126","author":"A Hoguet","year":"2019","unstructured":"Hoguet A, Chen PP, Junk AK, et al. The effect of anti-vascular endothelial growth factor agents on intraocular pressure and glaucoma: a report by the American Academy of Ophthalmology. Ophthalmology. 2019;126(4):611\u201322.","journal-title":"Ophthalmology"},{"key":"345_CR29","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1136\/bjo.2010.180729","volume":"95","author":"TJ Good","year":"2011","unstructured":"Good TJ, Kimura AE, Mandava N, Kahook MY. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol. 2011;95:1111\u20134.","journal-title":"Br J Ophthalmol"},{"issue":"9","key":"345_CR30","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/j.ophtha.2015.04.018","volume":"122","author":"KB Freund","year":"2015","unstructured":"Freund KB, Hoang QV, Saroj N, Thompson D. Intraocular pressure in patients with neovascular age-related macular degeneration receiving intravitreal aflibercept or ranibizumab. Ophthalmology. 2015;122(9):1802\u201310.","journal-title":"Ophthalmology"},{"issue":"2","key":"345_CR31","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3928\/23258160-20140306-08","volume":"45","author":"JB Fileta","year":"2014","unstructured":"Fileta JB, Scott IU, Flynn HW Jr. Meta-analysis of infectious endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmic Surg Lasers Imaging Retina. 2014;45(2):143\u20139.","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"8","key":"345_CR32","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1097\/IAE.0000000000001142","volume":"36","author":"LN Kim","year":"2016","unstructured":"Kim LN, Mehta H, Barthelmes D, Nguyen V, Gillies MC. Metaanalysis of real-world outcomes of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration. Retina. 2016;36(8):1418\u201331.","journal-title":"Retina"},{"key":"345_CR33","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ajo.2016.02.028","volume":"165","author":"N Rayess","year":"2016","unstructured":"Rayess N, Rahimy E, Storey P, et al. Postinjection endophthalmitis rates and characteristics following intravitreal bevacizumab, ranibizumab, and aflibercept. Am J Ophthalmol. 2016;165:88\u201393.","journal-title":"Am J Ophthalmol"},{"key":"345_CR34","doi-asserted-by":"crossref","unstructured":"Woo SJ, Veith M, Hamouz J, et al. Efficacy and safety of a proposed ranibizumab biosimilar product vs a reference ranibizumab product for patients with neovascular age-related macular degeneration: a randomized clinical trial. JAMA Ophthalmol. 2021;139(1):68\u201376.","DOI":"10.1001\/jamaophthalmol.2020.5053"},{"issue":"1","key":"345_CR35","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ophtha.2017.07.005","volume":"125","author":"V Daien","year":"2018","unstructured":"Daien V, Nguyen V, Essex RW, et al. Incidence and outcomes of infectious and noninfectious endophthalmitis after intravitreal injections for age-related macular degeneration. Ophthalmology. 2018;125(1):66\u201374.","journal-title":"Ophthalmology"},{"issue":"5","key":"345_CR36","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1097\/IAE.0000000000000801","volume":"36","author":"PD Williams","year":"2016","unstructured":"Williams PD, Chong D, Fuller T, Callanan D. Noninfectious vitritis after intravitreal injection of anti-VEGF agents: variations in rates and presentation by medication. Retina. 2016;36(5):909\u201313.","journal-title":"Retina"},{"issue":"1","key":"345_CR37","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ophtha.2020.06.028","volume":"128","author":"PU Dugel","year":"2021","unstructured":"Dugel PU, Singh RP, Koh A, et al. HAWK and HARRIER: ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2021;128(1):89\u201399.","journal-title":"Ophthalmology"},{"issue":"10","key":"345_CR38","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1038\/s41433-020-0853-9","volume":"34","author":"A Sharma","year":"2020","unstructured":"Sharma A, Kumar N, Parachuri N, et al. Brolucizumab and immunogenicity. Eye (Lond). 2020;34(10):1726\u20138.","journal-title":"Eye (Lond)"},{"issue":"9","key":"345_CR39","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/s41433-019-0434-y","volume":"33","author":"A Sharma","year":"2019","unstructured":"Sharma A, Kumar N, Kuppermann BD, Bandello F, Loewenstein A. Biotherapeutics and immunogenicity: ophthalmic perspective. Eye (Lond). 2019;33(9):1359\u201361.","journal-title":"Eye (Lond)"},{"issue":"5","key":"345_CR40","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.ajo.2009.06.014","volume":"148","author":"K Csaky","year":"2009","unstructured":"Csaky K, Do DV. Safety implications of vascular endothelial growth factor blockade for subjects receiving intravitreal anti-vascular endothelial growth factor therapies. Am J Ophthalmol. 2009;148(5):647\u201356.","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"345_CR41","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","volume":"123","author":"JA Wells","year":"2016","unstructured":"Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2016;123(6):1351\u20139.","journal-title":"Ophthalmology"},{"issue":"7","key":"345_CR42","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","volume":"119","author":"DF Martin","year":"2012","unstructured":"Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388\u201398.","journal-title":"Ophthalmology"},{"issue":"9900","key":"345_CR43","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0140-6736(13)61501-9","volume":"382","author":"U Chakravarthy","year":"2013","unstructured":"Chakravarthy U, Harding SP, Rogers CA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 2013;382(9900):1258\u201367.","journal-title":"Lancet"},{"issue":"1","key":"345_CR44","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","volume":"121","author":"U Schmidt-Erfurth","year":"2014","unstructured":"Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014;121(1):193\u2013201.","journal-title":"Ophthalmology"},{"key":"345_CR45","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ajo.2016.06.019","volume":"169","author":"F Esen","year":"2016","unstructured":"Esen F, Alhan O, Kuru P, Sahin O. Safety assessment and power analyses in published anti-vascular endothelial growth factor randomized controlled trials. Am J Ophthalmol. 2016;169:68\u201372.","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"345_CR46","doi-asserted-by":"crossref","first-page":"352","DOI":"10.4103\/ijo.IJO_1973_20","volume":"69","author":"JU Sheth","year":"2021","unstructured":"Sheth JU, Stewart MW, Khatri M, et al. Changing trends in the use of anti-vascular endothelial growth factor (anti-VEGF) biosimilars: insights from the Vitreoretinal Society of India Biosimilars of Anti-VEGF Survey. Indian J Ophthalmol. 2021;69(2):352\u20136.","journal-title":"Indian J Ophthalmol"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-021-00345-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-021-00345-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-021-00345-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T14:12:28Z","timestamp":1619532748000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-021-00345-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,17]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["345"],"URL":"https:\/\/doi.org\/10.1007\/s40123-021-00345-2","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,17]]},"assertion":[{"value":"3 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}